Mr. Pratap Sandhu reports

THE PRECISION PEPTIDE COMPANY TARGETS LAUNCH OF THE PEPTIDE PEN, EXPANDING ITS U.S.-MADE PRODUCT PLATFORM

The Precision Peptide Company Inc. is introducing the Peptide Pen, the company's second commercial product. The launch of the Peptide Pen is expected to represent a significant expansion of the company's product offering, building on its BPC-157 transdermal patch with a new precision injection delivery system.

Highlights:

• The company introduces expected launch of the Peptide Pen, its second commercial product, marking a significant expansion beyond transdermal patches into precision injection delivery;
• Designed, manufactured and tested in the United States in a cGMP-certified facility using medical-grade materials;
• Features a five-millilitre dosing configuration, a first for a combined pen-and-vial peptide device, offering significantly more capacity than the standard three-millilitre cartridges commonly available;
• Interchangeable cartridge system allows customers to switch between different peptide protocols using a single device, reducing cost and complexity;
• Commercial release targeted for August, 2026.

A new standard in peptide delivery

The Peptide Pen is the first combined pen-and-vial peptide device to feature a five-millilitre dosing configuration. Most pen-style peptide devices on the market use three-millilitre cartridges, which can require more frequent cartridge changes and create interruptions for customers on longer or higher-dose protocols. The five-millilitre configuration means fewer cartridge swaps, less waste and a more practical experience for customers managing continuing peptide regimens.

The device also features an interchangeable cartridge system. Rather than being locked into a single peptide or protocol, customers can load different cartridges into the same device. This gives customers the flexibility to manage multiple peptide protocols with one pen, rather than purchasing separate devices for each, reducing both cost and complexity.

Designed and made in the United States

The Peptide Pen is designed, manufactured and tested in the U.S. in a cGMP-certified facility (ISO 13485) using medical-grade materials throughout. U.S.-based design and manufacturing was a central consideration in the company's selection of a device partner.

The company has partnered with Casetides, a U.S.-based designer of peptide storage, transport and injection systems, to bring the Peptide Pen to market.

Product specifications

The Peptide Pen combines a peptide vial and injection mechanism into a single device. Additional product features include a mechanical click-dial for precision dosing, compatibility with 29G to 32G ultrafine needles, a medical-grade ABS polymer body with a stainless steel drive mechanism and borosilicate glass cartridges. The device is TSA compliant and comes with a lifetime warranty.

Building a multiproduct platform

The introduction of the Peptide Pen is the latest step in the company's strategy to build a broader product platform in the peptide wellness space. With two distinct delivery systems now in its product line, the company offers customers both a needle-free transdermal option and a precision injection option.

The company is targeting a commercial release of the Peptide Pen in August, 2026, through The Precision Peptide Company website.

Pratap Sandhu, chief executive officer of The Precision Peptide Company, commented:

"The Peptide Pen is our second product and it expands what we can offer customers. The five-millillitre configuration is a first for a combined pen-and-vial device. It means fewer cartridge changes and a better experience on longer protocols. The interchangeable vial system lets customers manage multiple peptides with one pen. It's designed and made in the U.S. in a cGMP-certified facility. Customers now have two delivery options from us, the transdermal patch and the Peptide Pen."

About The Precision Peptide Company Inc.

The Precision Peptide Company is a publicly traded wellness company building a next-generation platform for high-quality peptide formulations. By combining scientific formulation and innovative delivery technologies, the company creates products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.

We seek Safe Harbor.